A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug

BACKGROUND AND PURPOSE: ATB‐346 is a hydrogen sulfide (H(2)S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Pharmacol
Asıl Yazarlar: Wallace, John L., Nagy, Peter, Feener, Troy D., Allain, Thibault, Ditrói, Tamás, Vaughan, David J., Muscara, Marcelo N., de Nucci, Gilberto, Buret, Andre G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Themed Section: Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7024706/
https://ncbi.nlm.nih.gov/pubmed/30834513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14641
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller